Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Mimicking the microenvironment in chronic lymphocytic leukaemia - where does the journey go?

Asslaber D, Grössinger EM, Girbl T, Hofbauer SW, Egle A, Weiss L, Greil R, Hartmann TN.

Br J Haematol. 2013 Mar;160(5):711-4. doi: 10.1111/bjh.12151. Epub 2012 Dec 4. No abstract available.

PMID:
23205585
2.

Role of the microenvironment in chronic lymphocytic leukaemia.

Caligaris-Cappio F.

Br J Haematol. 2003 Nov;123(3):380-8. Review. No abstract available.

PMID:
14616995
4.

Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells.

Decker T, Schneller F, Sparwasser T, Tretter T, Lipford GB, Wagner H, Peschel C.

Blood. 2000 Feb 1;95(3):999-1006.

5.

Stimulation of B-chronic lymphocytic leukemia cells by murine fibroblasts, IL-4, anti-CD40 antibodies, and the soluble CD40 ligand.

Buske C, Gogowski G, Schreiber K, Rave-Fränk M, Hiddemann W, Wörmann B.

Exp Hematol. 1997 Apr;25(4):329-37.

PMID:
9131008
6.

Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia.

Biagi E, Rousseau R, Yvon E, Schwartz M, Dotti G, Foster A, Havlik-Cooper D, Grilley B, Gee A, Baker K, Carrum G, Rice L, Andreeff M, Popat U, Brenner M.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6916-23.

7.

CXCL12 is a costimulator for CD4+ T cell activation and proliferation in chronic lymphocytic leukemia patients.

Borge M, Nannini PR, Morande PE, Jancic C, Bistmans A, Bezares RF, Giordano M, Gamberale R.

Cancer Immunol Immunother. 2013 Jan;62(1):113-24. doi: 10.1007/s00262-012-1320-7. Epub 2012 Jul 29.

PMID:
22842611
8.

Effects of preactivated autologous T lymphocytes on CD80, CD86 and CD95 expression by chronic lymphocytic leukemia B cells.

Romano C, De Fanis U, Sellitto A, Dalla Mora L, Chiurazzi F, Giunta R, Rotoli B, Lucivero G.

Leuk Lymphoma. 2003 Nov;44(11):1963-71.

PMID:
14738151
9.

Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.

Fiorcari S, Martinelli S, Bulgarelli J, Audrito V, Zucchini P, Colaci E, Potenza L, Narni F, Luppi M, Deaglio S, Marasca R, Maffei R.

Haematologica. 2015 Feb;100(2):253-62. doi: 10.3324/haematol.2014.113217. Epub 2014 Nov 14.

10.

Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1.

Pedersen IM, Kitada S, Leoni LM, Zapata JM, Karras JG, Tsukada N, Kipps TJ, Choi YS, Bennett F, Reed JC.

Blood. 2002 Sep 1;100(5):1795-801.

11.

Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes.

Biagi E, Dotti G, Yvon E, Lee E, Pule M, Vigouroux S, Gottschalk S, Popat U, Rousseau R, Brenner M.

Blood. 2005 Mar 15;105(6):2436-42. Epub 2004 Nov 9.

12.

Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22.

Ghia P, Strola G, Granziero L, Geuna M, Guida G, Sallusto F, Ruffing N, Montagna L, Piccoli P, Chilosi M, Caligaris-Cappio F.

Eur J Immunol. 2002 May;32(5):1403-13.

13.

Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors.

Fluckiger AC, Rossi JF, Bussel A, Bryon P, Banchereau J, Defrance T.

Blood. 1992 Dec 15;80(12):3173-81.

14.

Direct cellular interaction with activated CD4(+) T cells overcomes hyporesponsiveness of B-cell chronic lymphocytic leukemia in vitro.

Tretter T, Schuler M, Schneller F, Brass U, Esswein M, Aman MJ, Huber C, Peschel C.

Cell Immunol. 1998 Oct 10;189(1):41-50.

PMID:
9758693
15.

CD180 functions in activation, survival and cycling of B chronic lymphocytic leukaemia cells.

Porakishvili N, Memon A, Vispute K, Kulikova N, Clark EA, Rai KR, Nathwani A, Damle RN, Chiorazzi N, Lydyard PM.

Br J Haematol. 2011 May;153(4):486-98. doi: 10.1111/j.1365-2141.2011.08605.x. Epub 2011 Mar 28.

PMID:
21443749
16.

Chronic lymphocytic leukemia cells induce anti-apoptotic effects of bone marrow stroma.

Plander M, Ugocsai P, Seegers S, Orsó E, Reichle A, Schmitz G, Hofstädter F, Brockhoff G.

Ann Hematol. 2011 Dec;90(12):1381-90. doi: 10.1007/s00277-011-1218-z. Epub 2011 Apr 5.

PMID:
21465189
17.

Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia.

Chu P, Deforce D, Pedersen IM, Kim Y, Kitada S, Reed JC, Kipps TJ.

Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3854-9. Epub 2002 Mar 12.

18.

Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy.

Dotti G, Savoldo B, Takahashi S, Goltsova T, Brown M, Rill D, Rooney C, Brenner M.

Exp Hematol. 2001 Aug;29(8):952-61.

PMID:
11495701
19.

In vitro engagement of CD3 and CD28 corrects T cell defects in chronic lymphocytic leukemia.

Bonyhadi M, Frohlich M, Rasmussen A, Ferrand C, Grosmaire L, Robinet E, Leis J, Maziarz RT, Tiberghien P, Berenson RJ.

J Immunol. 2005 Feb 15;174(4):2366-75.

20.

CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia.

Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ.

Blood. 2000 Nov 1;96(9):2917-24.

Supplemental Content

Support Center